Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. BAC

Go back to Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
(NASDAQ: PGEN) Delayed: 7.10 -0.04 (0.56%)
Previous Close $7.14    52 Week High $ 
Open $7.12    52 Week Low $ 
Day High $7.27    P/E N/A 
Day Low $7.08    EPS $ 
Volume 2,192,988